Grant Zeng's  Instablog

Full Index of Posts 36 posts, page 1 of 2

• ATOS: Any Retreat In Share Price Should Provide A Good Entry Opportunity

  Thu, May 9 • ATOS

• TKMR Is On Track To Advance TKM-Ebola Program

  Thu, May 9 • TKMR

• 2013 Will Be A Banner Year For GeoVax

  Fri, May 3

• Distribution Agreement With Millennium HealthCare Will Boost Atossa Topline For 2013

  Thu, May 2 • ATOS

• GeoVax Is On Track To Advance Its HIV/AIDS Vaccine Programs In 2013

  Tue, Mar 12 • GOVX.OB

• The FDA Letter Won't Impact Atossa’S Business Much

  Tue, Feb 26 • ATOS

• APDN: A Unique Anti-counterfeit Company Poised To Resume Growth In Second Half Of 2013

  Mon, Feb 25

• Bio-Path Shares Are Attractive Now

  Wed, Feb 20

• Current Decline In Share Price Is An Opportunity To Accumulate Shares

  Thu, Feb 14

• Galena Biopharma: Clinical Programs Remain On Track And Valuation Is Attractive

  Mon, Feb 11 • GALE

• NeoGenomics Is Poised To Grow Further In 2013

  Wed, Dec 19, 2012

• Galena On Track To Advance NeuVax

  Mon, Dec 10, 2012 • GALE

• Pressure BioSciences (PBIO), One Of The Most Undervalued Biotech Companies

  Thu, Nov 29, 2012

• Immunovaccine Is Making Progress In Advancing Its Clinical Programs

  Tue, Oct 9, 2012

• Novelos Is Advancing Three Candidates Based On Its Unique Diapeutic Platform

  Mon, Oct 8, 2012

• MethylGene Reports Encouraging Clinical And Preclinical Data

  Mon, Oct 8, 2012

• PBIO Continues To Move In A Positive Direction

  Tue, Jul 10, 2012

• Novelos' Initial Data From LIGHT Phase I/II Trial Are Very Encouraging

  Tue, Jun 19, 2012

• MethylGene: Initiating With An Outperform

  Mon, Jun 11, 2012

• Bio-Path Continues To Make Progress

  Mon, Jun 4, 2012

• Further Progress Made For DCVax-L Brain Cancer Clinical Trial

  Sun, May 20, 2012

• What Happened To Access Pharma In The Last Two Days?

  Fri, May 18, 2012

• First Cohort Of HOT Phase Ib In Solid Tumor Completed

  Tue, May 15, 2012

• Strategic Collaboration Means Better Penetration In The Sample Preparation Market

  Mon, May 7, 2012

• Initial LIGHT Data From Phase I/II Trial Are Encouraging

  Tue, Apr 24, 2012

• Expanded Collaboration With TDI Could Mean Increased Revenue

  Mon, Apr 23, 2012 • PBIO.OB

• Novelos (NVLT): Initiating With An Outperform

  Wed, Apr 18, 2012

• Pressure BioSciences Has Landed A Favorable Financing Deal

  Tue, Apr 17, 2012

• Advaxis Reports Positive Low Dose Cohort Phase II Trial Of ADXS-HPV For CIN 2/3

  Mon, Feb 27, 2012

• CYDY— Promising Antibody Technology For The Treatment Of HIV/FIV

  Wed, Feb 15, 2012

• Advaxis (ADXS) Is On Track To Achieve 2012 Goals

  Mon, Jan 30, 2012 • Biotech

• Amiket, Another Key Value Driver For EpiCept

  Tue, Jan 24, 2012 • Biotech

• Enrollment Of Phase II Clinical Trial Of ICT-107 Is Ahead Of Schedule

  Tue, Jan 24, 2012 • Biotech

• Galena Biopharma Initiates Phase III PRESENT Trial Of NeuVax Ahead Of Schedule

  Mon, Jan 23, 2012 • GALE

• Pressure BioSciences May Surprise Investors In 2012

  Tue, Jan 17, 2012 • PBIO.OB, long-ideas